NITO News & Events

N2OFF announced a comprehensive corporate rebranding to Nexentis Technologies and change in the trading symbol of the Company to "NXTS" on the Nasdaq Capital Market. The name change and the symbol change will take effect on the Nasdaq Capital Market on February 26, 2026. The company said, "The new name and brand are designed to reflect the Company's transformation into an innovative AI and data-driven computational biotech platform focused on mitochondrial biology, precision oncology and inflammatory metabolic diseases. At the core of this rebranding is the integration and scaling of MitoCareX Bio, now a wholly-owned subsidiary of the Company, which brings a proprietary discovery engine targeting the mitochondrial SLC25 carrier family using its MITOLINE algorithm and structure-guided virtual screening workflows. Nexentis intends to harness this platform to build a diversified pipeline of first-in-class small-molecule programs, while continuing to selectively manage its RTB solar energy investments as a non-core, value-optimizing asset base."

N2OFF recently announced that MitoCareX Bio has shown preliminary in vitro data demonstrating inhibition of pro-inflammatory responses in human immune cells using its proprietary discovery platform. The company said, "Using MITOLINE-derived models, MitoCareX has assembled a focused library of small-molecule candidates that is now being evaluated in a suite of proprietary in-vitro assays designed to capture mitochondrial function, inflammatory signalling, and metabolic readouts. The newly reported in vitro data show that selected candidates reduce key inflammatory markers in human immune cells, providing MitoCareX Bio with an initial line of evidence that mitochondrial carrier modulation can deliver anti-inflammatory benefit in human-relevant systems. These results support further in vivo validation and lead optimization across multiple inflammatory metabolic disease indications including diseases related to the metabolic syndrome."

N2OFF highlighted a newly published peer-reviewed study co-authored by Prof. Ciro Leonardo Pierri, co-founder of MitoCareX Bio. The article, appearing in the Journal of Translational Medicine, investigates SLC25A mitochondrial carriers as potential biomarkers and therapeutic targets for dysfunctions induced by spaceflight conditions, including microgravity and cosmic radiation. The study, titled "SLC25A mitochondrial carriers as biomarkers and therapeutic targets of spaceflight-induced dysfunction: the ADP/ATP carrier as a structural case study," was published online on December 30. The work integrates transcriptomic data from NASA's Open Science Data Repository, examining the expression of 53 SLC25A genes in osteocytes, human bone marrow-derived mesenchymal stem cells, and mouse brain tissue exposed to microgravity and spaceflight-related stressors. The analysis identified differential regulation of multiple SLC25A carriers under spaceflight conditions, supporting their potential utility as biomarkers of mitochondrial and metabolic dysfunction. The ADP/ATP carrier AAC3 was further examined as a structural case study, based on comparative modeling and structure-function analyses to illustrate how carrier conformational features may be targeted to rescue mitochondrial bioenergetics under stress. While this independent academic research- conducted in collaboration with the University of Bari "Aldo Moro" and the University of Pittsburgh-was not performed under MitoCareX Bio's auspices, it directly aligns with the Company's core scientific area of focus on mitochondrial carrier biology. MitoCareX Bio applies proprietary approaches, including the MITOLINE algorithm to virtually model, screen and validate small-molecule modulators targeting the SLC25A family of mitochondrial carriers. These proteins, central to cellular energy metabolism, play central roles in hard-to-treat indications including in several types of cancer, metabolic diseases related to the metabolic syndrome, and are also implicated in rare inherited disorders associated with neuromuscular degeneration, which share mechanistic similarities with physiological alterations observed in astronauts.

N2OFF announced that MitoCareX Bio has shown preliminary in vitro data demonstrating inhibition of pro--inflammatory responses in human immune cells using its proprietary discovery platform. Using MITOLINE-derived models, MitoCareX has assembled a focused library of small-molecule candidates that is now being evaluated in a suite of proprietary in-vitro assays designed to capture mitochondrial function, inflammatory signalling, and metabolic readouts. The newly reported in vitro data show that selected candidates reduce key inflammatory markers in human immune cells, providing an initial line of evidence that mitochondrial carrier modulation can deliver anti-inflammatory benefit in human-relevant systems. These results support further in vivo validation and lead optimization across multiple inflammatory metabolic disease indications including diseases related to the metabolic syndrome.